CD20, generalidades básicas-moleculares y su posible relación como marcador de mal pronóstico en leucemia

Middleton O, Wheadon H, Michie AM. Molecular aspects of Innate Immunity. Classical Complement Pathway. En: Ratcliffe MJH, editor. Encyclopedia of Immunobiology. Oxford: Academic Press; 2016. p. 321-3. https://doi.org/10.1016/B978-0-12-374279-7.02014-2

Prevodnik VK, Lavrenčak J, Horvat M, Novakovič BJ. The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011;6:33. https://doi.org/10.1186/1746-1596-6-33

Esteban RE, Christianne B, Alvaro A, Demichelis-Gómez R. Prognostic Effect of CD20 Expression in Adult B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2018;18(5):361-7. https://doi.org/10.1016/j.clml.2018.02.013

Levato L, Molica S. Rituximab in the management of acute lymphoblastic leukemia. Expert Opin Biol Ther. 2018;18(2):221-6. https://doi.org/10.1080/14712598.2018.1425389

Safdari Y, Ahmadzadeh V, Farajnia S. CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Invest New Drugs. 2016;34(4):497-512. https://doi.org/10.1007/s10637-016-0349-4

Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. https://doi.org/10.1038/bcj.2017.53

Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016;91(11):1645-66. https://doi.org/10.1016/j.mayocp.2016.09.010

Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control CCC. 2015;26(11):1627-42. https://doi.org/10.1007/s10552-015-0657-6

Miranda-Filho A, Piñeros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5(1):e14-24. https://doi.org/10.1016/S2352-3026(17)30232-6

Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood. 2017;130(15):1699-705. https://doi.org/10.1182/blood-2017-04-778225

Globocan 2020. Global Cancer Observatory. Disponible en: https://gco.iarc.fr/

Curado MP, Pontes T, Guerra-Yi ME, Cancela M de C. Leukemia mortality trends among children, adolescents, and young adults in Latin America. Rev Panam Salud Publica Pan Am J Public Health. febrero de 2011;29(2):96-102. Disponible en: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892011000200004

Leucemias en Colombia, ¿cuál es el panorama de la enfermedad en la población adulta? Cuenta de Alto Costo. 2021. Disponible en: https://cuentadealtocosto.org/site/cancer/leucemias-en-colombia-cual-es-el-panorama-de-la-enfermedad-en-la-poblacion-adulta/

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO classification of tumours of haematopoietic and lymphoid tissues. Fourth edition. Vol. 2. Lyon, France: IARC; 2017. p. 200-2.

Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol Baltim Md 1950. 1980;125(4):1678-85. https://doi.org/10.4049/jimmunol.125.4.1678

Oettgen HC, Bayard PJ, Van Ewijk W, Nadler LM, Terhorst CP. Further biochemical studies of the human B-cell differentiation antigens B1 and B2. Hybridoma. 1983;2(1):17-28. https://doi.org/10.1089/hyb.1983.2.17

Tedder TF, McIntyre G, Schlossman SF. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. Mol Immunol. 1988;25(12):1321-30. https://doi.org/10.1016/0161-5890(88)90047-8

Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7(3):711-7. https://doi.org/10.1002/j.1460-2075.1988.tb02867.x

Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol Baltim Md 1950. 1998;161(7):3242-8. https://doi.org/10.4049/jimmunol.161.7.3242

Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A. 1988;85(1):208-12. https://doi.org/10.1073/pnas.85.1.208

Hupp K, Siwarski D, Mock BA, Kinet JP. Gene mapping of the three subunits of the high affinity FcR for IgE to mouse chromosomes 1 and 19. J Immunol Baltim Md 1950. 1989;143(11):3787-91. https://doi.org/10.4049/jimmunol.143.11.3787

Adra CN, Lelias JM, Kobayashi H, Kaghad M, Morrison P, Rowley JD, et al. Cloning of the cDNA for a hematopoietic cell-specific protein related to CD20 and the beta subunit of the high-affinity IgE receptor: evidence for a family of proteins with four membrane-spanning regions. Proc Natl Acad Sci U S A. 1994;91(21):10178-82. https://doi.org/10.1073/pnas.91.21.1017

Tedder TF, Klejman G, Disteche CM, Adler DA, Schlossman SF, Saito H. Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. J Immunol Baltim Md 1950. 1988;141(12):4388-94. https://doi.org/10.4049/jimmunol.141.12.4388

Tedder TF, Klejman G, Schlossman SF, Saito H. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol Baltim Md 1950. 1989;142(7):2560-8. https://doi.org/10.4049/jimmunol.142.7.2560

Stamenkovic I, Seed B. Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein. J Exp Med. 1988;167(6):1975-80. https://doi.org/10.1084/jem.167.6.1975

Thévenin C, Lucas BP, Kozlow EJ, Kehrl JH. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem. 1993;268(8):5949-56. Available from: https://www.jbc.org/article/S0021-9258(18)53411-6/pdf

Rieckmann P, Wilson GL, Thevenin C, Hong JX, Kehrl JH. Analysis of cis-acting elements present in the CD20/B1 antigen promoter. J Immunol. 1991;147(11):3994-9. https://doi.org/10.4049/jimmunol.147.11.3994

Thevenin C, Rieckmann P, Kozlow EJ, Kehrl JH. Identification of a diverged octamer binding site important in the B cell-specific expression of the CD20 gene. Trans Assoc Am Physicians. 1992;105:15-24. PMID: 1285015

Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 Promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. blood. 1997;90(10):3984-95. https://doi.org/10.1182/blood.V90.10.3984

Słabicki M, Lee KS, Jethwa A, Sellner L, Sacco F, Walther T, et al. Dissection of CD20 regulation in lymphoma using RNAi. Leukemia. 2016;30(12):2409-12. https://doi.org/10.1038/leu.2016.230

Tomita A, Hiraga J, Kiyoi H, Ninomiya M, Sugimoto T, Ito M, et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol. 2007;86(1):49-57. https://doi.org/10.1532/IJH97.07028

Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113(20):4885-93. https://doi.org/10.1182/blood-2008-08-175208

Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol. 1996;106(1):78-81. https://doi.org/10.1093/ajcp/106.1.78

Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, et al. Features of Human CD3+CD20+ T Cells. J Immunol. 2016;197(4):1111-7. https://doi.org/10.4049/jimmunol.1600089

Tedder TF, Schlossman SF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem. 1988;263(20):10009-15. Available from: https://www.jbc.org/article/S0021-9258(19)81618-6/pdf

Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15(9):450-4. https://doi.org/10.1016/0167-5699(94)90276-3

Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 2003;278(43):42427-34. https://doi.org/10.1074/jbc.M308802200

Parekh AB. Store-operated Ca2+ entry: dynamic interplay between endoplasmic reticulum, mitochondria and plasma membrane. J Physiol. 2003;547(Pt 2):333-48. https://doi.org/10.1113/jphysiol.2002.034140

Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121(5):1121-32. https://doi.org/10.1083/jcb.121.5.1121

Szöllósi J, Horejsí V, Bene L, Angelisová P, Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol. 1996;157(7):2939-46. https://doi.org/10.4049/jimmunol.157.7.2939

Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem. 2008;283(27):18545-52. https://doi.org/10.1074/jbc.M800784200

Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985;135(2):973-9. https://doi.org/10.4049/jimmunol.135.2.973

Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, et al. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018;32(9):2028-31. https://doi.org/10.1038/s41375-018-0211-0

Petrie RJ, Deans JP. Colocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid rafts. J Immunol. 2002;169(6):2886-91. https://doi.org/10.4049/jimmunol.169.6.2886

Kozlova V, Ledererova A, Ladungova A, Peschelova H, Janovska P, Slusarczyk A, et al. CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. PloS One. 2020;15(3):e0229170. https://doi.org/10.1371/journal.pone.0229170

Li H, Ayer LM, Polyak MJ, Mutch CM, Petrie RJ, Gauthier L, et al. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem. 2004;279(19):19893-901. https://doi.org/10.1074/jbc.M400525200

Janas E, Priest R, Malhotra R. Functional role of lipid rafts in CD20 activity? Biochem Soc Symp. 2005;(72):165-75. https://doi.org/10.1042/bss0720165

Bychkov A, Jung CK. Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance. Hum Pathol. 2018;71:74-83. https://doi.org/10.1016/j.humpath.2017.10.015

Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol San Diego Calif. 2012;65:335-59. https://doi.org/10.1016/B978-0-12-397927-8.00011-7

Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, et al. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther J Am Soc Gene Ther. 2012;20(5):1056-62. https://doi.org/10.1038/mt.2012.27

Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Rémy-Martin JP, Callanan M, et al. Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to Rituximab resistance. Blood. 2010;115(12):2420-9. https://doi.org/10.1182/blood-2009-06-229112

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, et al. New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies. Exp Hematol Oncol. 2015;5:7. https://doi.org/10.1186/s40164-016-0036-3

Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest. 2006;35(1):93-114. https://doi.org/10.1080/08820130500496878

Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20(5):1278-87. https://doi.org/10.1200/JCO.2002.20.5.1278

Tzankov A, Krugmann J, Fend F, Fischhofer M, Greil R, Dirnhofer S. Prognostic significance of CD20 expression in classical Hodgkin Lymphoma: A clinicopathological study of 119 cases. Clin Cancer Res. 2003;9(4):1381-6. Available from: https://aacrjournals.org/clincancerres/article/9/4/1381/202356/Prognostic-Significance-of-CD20-Expression-in

Quintanilla-Martinez L, Preffer F, Rubin D, Ferry JA, Harris NL. CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol. 1994;102(4):483-9. https://doi.org/10.1093/ajcp/102.4.483

Buckner CL, Christiansen LR, Bourgeois D, Lazarchick JJ, Lazarchick J. CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls. Ann Clin Lab Sci. 2007;37(3):263-7. Available from: http://www.annclinlabsci.org/content/37/3/263.long

Matnani RG, Stewart RL, Pulliam J, Jennings CD, Kesler M. Peripheral T-Cell Lymphoma with Aberrant Expression of CD19, CD20, and CD79a: Case Report and Literature Review. Case Rep Hematol. 2013;2013:e183134. https://doi.org/10.1155/2013/183134

Das DK. Nucleolar positivity for CD20: a diagnostic aid in neoplasms of T-cell lineage? Acta Cytol. 2005;49(4):365-72. https://doi.org/10.1159/000326167

Kumar J, Khan AA, Saraf A, Bhargava M. Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia. Indian J Hematol Blood Transfus. 2014;30(1):16-8. https://doi.org/10.1007/s12288-012-0216-1

Raponi S, De Propris MS, Intoppa S, Milani ML, Vitale A, Elia L, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;52(6):1098-107. https://doi.org/10.3109/10428194.2011.559668

Borowitz MJ, Shuster J, Carroll AJ, Nash M, Look AT, Camitta B, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood. 1997;89(11):3960-6. https://doi.org/10.1182/blood.V89.11.3960

Maury S, Huguet F, Leguay T, Lacombe F, Maynadié M, Girard S, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95(2):324-8. https://doi.org/10.3324/haematol.2009.010306

Isshiki Y, Ohwada C, Sakaida E, Onoda M, Aotsuka N, Tanaka H, et al. CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy. Jpn J Clin Oncol. 2017;47(11):1047-54. https://doi.org/10.1093/jjco/hyx126

Yang S, Wang J, Zhao T, Jia J, Zhu H, Jiang H, et al. CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia. Oncotarget. 2017;8(62):105397-406. https://doi.org/10.18632/oncotarget.22207

Thomas DA, O’Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25):6330-7. https://doi.org/10.1182/blood-2008-04-151860

Alvarado-Ibarra M, Trejo-Gómora J, López-Hernández M, Álvarez-Vera JL, Ortiz-Zepeda SM. Influencia pronóstica del CD20+ en la supervivencia libre de recaída y en los resultados terapéuticos de pacientes adultos con leucemia linfoblástica aguda de novo sometidos a quimioterapia intensiva. Rev Hematol. 2015;16(3):189-97. Disponible en: https://www.medigraphic.com/pdfs/hematologia/re-2015/re153b.pdf

Alduailej H, Kanfar S, Bakhit K, Raslan H, Alsaber A, Bashawri L, et al. Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy. Clin Lymphoma Myeloma Leuk. 2020;20(9):e560-8. https://doi.org/10.1016/j.clml.2020.04.008

Solano-Genesta M, Tarín-Arzaga L, Velasco-Ruiz I, Lutz-Presno JA, González-Llano O, Mancías-Guerra C, et al. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. Hematol Amst Neth. 2012;17(2):66-70. https://doi.org/10.1179/102453312X13221316477741

Mannelli F, Gianfaldoni G, Intermesoli T, Cattaneo C, Borlenghi E, Cortelazzo S, et al. CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. Haematologica. 2012;97(4):568-71. https://doi.org/10.3324/haematol.2011.054064

Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, et al. Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. Blood. 2011;117(19):5261-3. https://doi.org/10.1182/blood-2011-01-329573

Colombia. Ministerio de salud y Proteccion Social. Guía de práctica clínica para la detección, tratamiento y seguimiento de leucemias linfoblástica y mieloide en población mayor de 18 años. Guía No. 34. Bogotá, D.C: Ministerio de Salud y Protección Social; 2017. 193 p. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc-profesionales-leucemias-linfoblastica-mieloide-mayores-18-anos.pdf

Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788-801. https://doi.org/10.1002/cncr.20668

Xu W, Li JY, Qian SX, Wu HX, Lu H, Chen LJ, et al. Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia. Leuk Res. 2008;32(6):930-5. https://doi.org/10.1016/j.leukres.2007.10.019

Morris K, Weston H, Mollee P, Marlton P, Gill D, Kennedy G. Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population. Leuk Lymphoma. 2011;52(1):85-91. https://doi.org/10.3109/10428194.2010.532889

Combariza Juan Felipe, Casas Claudia Patricia, Rodriguez Neira Myriam Lucía, Cardona Zorrilla Andrés Felipe, Ospina León Edgar Guillermo, Grajales Marco. Supervivencia en adultos con leucemia linfoide aguda de novo tratados con el esquema HyperCVAD en el Instituto Nacional de Cancerología (Colombia), entre enero de 2001 y junio de 2005. Rev Colomb Cancerol. 2007;11(2):92-100. Disponible en: https://www.imbiomed.com.mx/articulo.php?id=49610

Ramos-Peñafiel CO, Cabrera-García Á, Rozen-Fuller E, González-León G, Balderas C, Kassack-Ipiña JJ, et al. Comparación del Hyper-CVAD con un régimen institucional en el tratamiento de la leucemia linfoblástica aguda del adulto en un hospital de México. Rev Peru Med Exp Salud Publica. 2014;31(3):525-9. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342014000300018

Arteaga-Ortiz L, Buitrón-Santiago N, Rosas-López A, Rosas-Arzate G, Armengolt-Jiménez A, Aguayo A, et al. Experiencia del INCMNSZ en pacientes adultos con leucemia linfoide aguda. Cohorte 2003-2007 con esquemas de tratamiento Hiper-CVAD y Protocolo 0195. Rev Investig Clin. 2008;60(6):459-69. Available from: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=41257

Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90(6):2188-95. https://doi.org/10.1182/blood.V90.6.2188

Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569-80. https://doi.org/10.1002/cncr.21776

Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and Rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880-9. https://doi.org/10.1200/JCO.2009.26.9456

Nam J, Milenkovski R, Yunger S, Geirnaert M, Paulson K, Seftel M. Economic evaluation of Rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. J Med Econ. 2018;21(1):47-59. https://doi.org/10.1080/13696998.2017.1372230

Sugimoto T, Tomita A, Hiraga J, Shimada K, Kiyoi H, Kinoshita T, et al. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun. 2009;390(1):48-53. https://doi.org/10.1016/j.bbrc.2009.09.059

Hato T, Yamanouchi J, Tamura T, Hojo N, Niiya Y, Kohno M, et al. Existence of leukemic clones resistant to both imatinib mesylate and Rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. Int J Hematol. 2004;80(1):62-6. https://doi.org/10.1532/IJH97.04033